Life-Sciences Industry Would Pay £10M In Fees Each Year To UK NICE Under Proposal
Executive Summary
England’s department of health is again consulting on plans to allow the health technology appraisal body NICE to charge companies for conducting appraisals.
You may also be interested in...
Moonshot Projects In Life Sciences Strategy Can Lift UK Over Brexit Hurdle
The long-awaited UK Life Sciences Strategy, part of the industrial strategy proposed after the May government took office in summer 2016, was released today. With input from major medtech organizations and UK-based pharma groups it charts a course ahead for the £64bn national life-sciences industry as the UK seeks to embrace its post-EU future.
NICE Cost Recovery Plans Pause Is Welcome News For UK Industry
UK health technology body NICE will wait for the government to finalize its life sciences strategy before deciding on whether to go ahead with its plan to levy a fee for technology appraisals. Pharmaceutical and medtech companies say the delay will allow more time for their concerns over the proposal to be explored.
As Appraisal Fees Loom, NICE Says No To Industry Calls For Reform
A proposal by the UK's HTA body NICE to charge companies for technology appraisals has raised several issues, such as the need for reforms to the HTA process, ensuring independence and credibility of appraisals, greater accountability and transparency at NICE, and the impact of fees on bringing new medicines to market.